Jounce Therapeutics to Participate in William Blair’s Biotech Focus Conference

Magenta Therapeutics Appoints Caren Deardorf As Chief Commercial Officer

Abata Therapeutics Launches to Usher in New Era of Cell Therapy Using Targeted Regulatory T Cells to Treat Serious Autoimmune and Inflammatory Diseases

Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement with Gilead Sciences and FDA Clearance of Investigational New Drug Application for Anti-CCR8 Antibody

Magenta Therapeutics Appoints Thomas Beetham As Chief Legal Officer

Nurix Therapeutics Announces Upcoming Presentation Of NX-5948 Preclinical Data At The EULAR 2021 Virtual Congress

Voyager Therapeutics Announces Strategic Shift And Leadership Transitions

Flare Therapeutics Launches with $82 Million Series A Financing to Advance Precision Oncology Pipeline based on Novel Drug Discovery Approach for Transcription Factors

Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-024, a Novel Precision Medicine Product Candidate for Patients with Severe Insulin Resistant Diabetic Nephropathy (DN)

Magenta Therapeutics Announces $86.4 Million Common Stock Investment From Multiple Investors

Voyager Therapeutics Presents New Preclinical Data Showing Reduction Of Pathological Tau With Vectorized Anti-Tau Antibody

Magenta Therapeutics Announces Positive Preliminary Results From Phase 2 Clinical Trial Of MGTA-145 In Multiple Myeloma And Provides An Update On Its Anticipated Clinical Study With MGTA-117

Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across The Blood Brain Barrier, Widespread CNS Transduction In Non-Human Primates

Allena Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress

Sesen Bio Reports First Quarter 2021 Financial Results and Commercial Launch Readiness Update in the US for Vicineum™

Voyager Therapeutics Announces First Quarter 2021 Financial Results And Corporate Updates

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

Fulcrum Therapeutics Appoints Christopher Morabito, M.D. as Chief Medical Officer

Magenta Therapeutics Reports First Quarter Financial Results And Recent Program Highlights

Faze Medicines Appoints Douglas Kerr, M.D., Ph.D., to its Board of Directors

Sesen Bio Announces Commercial Launch Readiness Progress as the Company Approaches the Potential Approval and Launch of Vicineum™

Jounce Therapeutics Reports First Quarter 2021 Financial Resultsj

MOMA Therapeutics Appoints Peter Hammerman, M.D., Ph.D., as Chief Scientific Officer

Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting

Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the Phase 2 SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy 24th Annual Meeting

Voyager Therapeutics Announces Upcoming Data Presentations At The American Society Of Gene And Cell Therapy Virtual 2021 Annual Meeting

Voyager Therapeutics Receives FDA Clearance Of IND Application For Gene Therapy Candidate VY-HTT01 For Treatment Of Huntington’s Diseasev

Cedilla Therapeutics Appoints Chris Bowden, M.D. to its Board of Directorsc

Ambys Medicines Appoints Alan Smith, Ph.D., Chief Technology Officer

Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors

Goldfinch Bio Expands Board of Directors with Appointments of Meryl Zausner, Hon. William “Mo” Cowan and Tyrell Rivers, Ph.D.

Tango Therapeutics And BCTG Acquisition Corp. Announce Merger Agreement To Create Publicly Listed Precision Medicine Company Focused On The Next Generation Of Targeted Cancer Therapies

Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results And Provides A Corporate Update

Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific Officer

Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting

Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference

Magenta Therapeutics To Participate In The Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference

Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development

Tango Therapeutics Appoints Mace Rothenberg, Md, And Lesley Ann Calhoun, Cpa, To Board Of Directors

Maze Therapeutics Appoints Atul Dandekar as Chief Strategy Officer and Expands Board of Directors

Maze Therapeutics Reveals Its Initial Three Lead Programs Targeting Underlying Genetic Drivers of Life-threatening Diseases

Decibel Therapeutics Added to Russell 2000 Index

Sesen Bio and Qilu Pharmaceutical Announce Approval of IND Application in China for Vicineum™

Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Pliant Therapeutics Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner